The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Kering Eyewear has agreed to buy Italian sunglass lens maker Lenti from Safilo , the unit of French luxury group Kering said on Tuesday, as it pushes for greater control of its supply chain.

Imfinzi is approved for muscle-invasive bladder cancer and is under investigation in various stages and combinations for bladder cancer treatment. ... The POTOMAC trial is a randomized, open-label, ...

Durvalumab (Imfinzi) in combination with chemotherapy followed by single-agent durvalumab has received FDA approval for the treatment of muscle-invasive bladder cancer after radical cystectomy. This ...

References: Imfinzi ® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer. News release. AstraZeneca. March 31, 2025 ...

NIAGARA is a randomized, open-label, multi-center, global Phase III trial evaluating perioperative IMFINZI as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1,063 ...

NIAGARA is a randomised, open-label, multi-centre, global Phase III trial evaluating perioperative Imfinzi as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1,063 ...

The efficacy of neoadjuvant Imfinzi was evaluated in the phase 3 NIAGARA trial, a randomized, open-label, multicenter investigation which enrolled 1,063 patients who were candidates for radical ...

Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed, with final ...

IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...